NEW YORK (GenomeWeb News) – Vermillion said today that it has tapped investment bank ThinkPanmure to help it identify and evaluate “strategic alternatives” for maximizing shareholder value.
Vermillion said it plans to work with ThinkPanmure on ways to “enhance the potential” of its OVA1 and VASCLIR proteomic tests and its pipeline of proprietary biomarkers, but added that “no assurances can be given that this evaluation will lead to any specific action or transaction.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.